HMGB1 plasma levels are shown to be associated with severity of the disease, survival, and mortality of bacterial pneumonia complicated by ARDS, meanwhile, treatment with HMGB1-specific antagonist revealed improved survival in preclinical animal models of acute inflammation (22–24). Here, HMGB1 is linked to bacterial pneumonia.